Answer
Letermovir (Prevymis) is indicated for CMV disease prophylaxis in CMV-seronegative adult and paediatric kidney transplant recipients weighing at least 40 kg who received their transplant from a CMV-seropositive donor (D+/R−).
Sources for this answer
- PREVYMIS 240 mg film-coated tabletsMerck Sharp & Dohme (UK) Limited · emc · SmPC §4.1 Therapeutic Indications · Version 14Document updated
Sources checked